These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 11956959)
1. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data. Briani C; Ruggero S; Naccarato M; Cagnin A; Ricchieri GL; Pasqui L; Pizzolato G; Battistin L J Neural Transm (Vienna); 2002 Mar; 109(3):393-8. PubMed ID: 11956959 [TBL] [Abstract][Full Text] [Related]
2. CSF levels of beta-amyloid 1-42, tau and phosphorylated tau protein in CADASIL. Formichi P; Parnetti L; Radi E; Cevenini G; Dotti MT; Federico A Eur J Neurol; 2008 Nov; 15(11):1252-5. PubMed ID: 18803653 [TBL] [Abstract][Full Text] [Related]
3. Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. Hohman TJ; Dumitrescu L; Barnes LL; Thambisetty M; Beecham G; Kunkle B; Gifford KA; Bush WS; Chibnik LB; Mukherjee S; De Jager PL; Kukull W; Crane PK; Resnick SM; Keene CD; Montine TJ; Schellenberg GD; Haines JL; Zetterberg H; Blennow K; Larson EB; Johnson SC; Albert M; Bennett DA; Schneider JA; Jefferson AL; JAMA Neurol; 2018 Aug; 75(8):989-998. PubMed ID: 29801024 [TBL] [Abstract][Full Text] [Related]
5. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand. Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431 [TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758 [TBL] [Abstract][Full Text] [Related]
7. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. de Souza LC; Chupin M; Lamari F; Jardel C; Leclercq D; Colliot O; Lehéricy S; Dubois B; Sarazin M Neurobiol Aging; 2012 Jul; 33(7):1253-7. PubMed ID: 21489655 [TBL] [Abstract][Full Text] [Related]
15. Biomarkers of Alzheimer's disease: the present and the future. Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316 [TBL] [Abstract][Full Text] [Related]
16. Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia. Le Bastard N; Coart E; Vanderstichele H; Vanmechelen E; Martin JJ; Engelborghs S J Alzheimers Dis; 2013; 33(1):117-31. PubMed ID: 22936010 [TBL] [Abstract][Full Text] [Related]
17. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Engelborghs S; Sleegers K; Cras P; Brouwers N; Serneels S; De Leenheir E; Martin JJ; Vanmechelen E; Van Broeckhoven C; De Deyn PP Brain; 2007 Sep; 130(Pt 9):2320-6. PubMed ID: 17586559 [TBL] [Abstract][Full Text] [Related]
19. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Braak H; Zetterberg H; Del Tredici K; Blennow K Acta Neuropathol; 2013 Nov; 126(5):631-41. PubMed ID: 23756600 [TBL] [Abstract][Full Text] [Related]
20. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]